<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:hpo ids='HP_0001513'>Obesity</z:hpo> and its related <z:mp ids='MP_0005266'>metabolic abnormalities</z:mp>, including <z:hpo ids='HP_0000855'>insulin resistance</z:hpo>, alterations in the insulin-like growth factor-1 (IGF-1)/IGF-1 receptor (IGF-1R) axis, and the state of <z:hpo ids='HP_0011010'>chronic</z:hpo> <z:mp ids='MP_0001845'>inflammation</z:mp>, increase the risk of <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e>) and <z:hpo ids='HP_0001402'>hepatocellular carcinoma</z:hpo> (<z:mp ids='MP_0003331'>HCC</z:mp>) </plain></SENT>
<SENT sid="1" pm="."><plain>However, these findings also indicate that the <z:e sem="disease" ids="C0025517" disease_type="Disease or Syndrome" abbrv="">metabolic disorders</z:e> caused by <z:hpo ids='HP_0001513'>obesity</z:hpo> might be effective targets to prevent the development of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> and <z:mp ids='MP_0003331'>HCC</z:mp> in <z:mp ids='MP_0001261'>obese</z:mp> individuals </plain></SENT>
<SENT sid="2" pm="."><plain>Green tea <z:chebi fb="0" ids="23053">catechins</z:chebi> (GTCs) possess anticancer and chemopreventive properties against <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> in various organs, including the colorectum and liver </plain></SENT>
<SENT sid="3" pm="."><plain>GTCs have also been known to exert anti-<z:hpo ids='HP_0001513'>obesity</z:hpo>, <z:chebi fb="0" ids="35526">antidiabetic</z:chebi>, and anti-inflammatory effects, indicating that GTCs might be useful for the prevention of <z:hpo ids='HP_0001513'>obesity</z:hpo>-associated colorectal and <z:e sem="disease" ids="C1512409" disease_type="Neoplastic Process" abbrv="">liver carcinogenesis</z:e> </plain></SENT>
<SENT sid="4" pm="."><plain>Further, branched-chain amino acids (BCAA), which improve protein <z:hpo ids='HP_0004395'>malnutrition</z:hpo> and prevent progressive <z:hpo ids='HP_0001399'>hepatic failure</z:hpo> in patients with <z:hpo ids='HP_0011010'>chronic</z:hpo> <z:e sem="disease" ids="C0023895" disease_type="Disease or Syndrome" abbrv="">liver diseases</z:e>, might be also effective for the suppression of <z:hpo ids='HP_0001513'>obesity</z:hpo>-related <z:e sem="disease" ids="C0596263" disease_type="Neoplastic Process" abbrv="">carcinogenesis</z:e> because oral supplementation with BCAA reduces the risk of <z:mp ids='MP_0003331'>HCC</z:mp> in <z:mp ids='MP_0001261'>obese</z:mp> cirrhotic patients </plain></SENT>
<SENT sid="5" pm="."><plain>BCAA shows these beneficial effects because they can improve <z:hpo ids='HP_0000855'>insulin resistance</z:hpo> </plain></SENT>
<SENT sid="6" pm="."><plain>Here, we review the detailed relationship between <z:mp ids='MP_0005266'>metabolic abnormalities</z:mp> and the development of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> and <z:mp ids='MP_0003331'>HCC</z:mp> </plain></SENT>
<SENT sid="7" pm="."><plain>We also review evidence, especially that based on our basic and clinical research using GTCs and BCAA, which indicates that targeting <z:mp ids='MP_0005266'>metabolic abnormalities</z:mp> by either pharmaceutical or nutritional intervention may be an effective strategy to prevent the development of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> and <z:mp ids='MP_0003331'>HCC</z:mp> in <z:mp ids='MP_0001261'>obese</z:mp> individuals </plain></SENT>
</text></document>